Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 48Breast Neoplasms 48Lung Neoplasms 34Ovarian Neoplasms 33Fallopian Tube Neoplasms 22Carcinoma, Ovarian Epithelial 21Adenocarcinoma of Lung 16Unspecified Adult Solid Tumor, Protocol Specific 13Brenner Tumor 11Adenocarcinoma, Bronchiolo-Alveolar 11Head and Neck Neoplasms 10Breast Neoplasms, Male 10Neoplasm Metastasis 9Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasms 7Esophageal Neoplasms 7Endometrial Neoplasms 7Adenocarcinoma Of Esophagus 6Urinary Bladder Neoplasms 5Oropharyngeal Neoplasms 5Melanoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Peritoneal Neoplasms 4Mouth Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × Paclitaxel × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡